Optogenetics is a technique where a cell is transduced with a light-sensitive ion channel. This technique can be used to control muscle cell contraction in conjunction with commonly used viral vectors. However, this technique has not yet become widely applied. In this study, we discuss the mechanisms and techniques involved in opsin transfer to muscle tissue, the clinical applicability of these approaches, and the major limitations facing this technique.
NagelG, BraunerM, LiewaldJF, et al.Light activation of channelrhodopsin-2 in excitable cells of Caenorhabditis elegans triggers rapid behavioral responses. Curr Biol, 2005; 15(24):2279–2284; doi: 10.1016/j.cub.2005.11.032
3.
FlotteTR, TrapnellBC, HumphriesM, et al.Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: Interim results. Hum Gene Ther, 2011; 22(10):1239–1247; doi: 10.1089/hum.2011.053
4.
CalderonJC, BolanosP, CaputoC. The excitation-contraction coupling mechanism in skeletal muscle. Biophys Rev, 2014; 6(1):133–160; doi: 10.1007/s12551-013-0135-x
5.
RorsmanNJG, TaCM, GarnettH, et al.Defining the ionic mechanisms of optogenetic control of vascular tone by channelrhodopsin-2. Br J Pharmacol, 2018; 175(11):2028–2045; doi: 10.1111/bph.14183
6.
AlilainWJ, LiX, HornKP, et al.Light-induced rescue of breathing after spinal cord injury. J Neurosci, 2008; 28(46):11862–11870; doi: 10.1523/JNEUROSCI.3378-08.2008
LlewellynME, ThompsonKR, DeisserothK, et al.Orderly recruitment of motor units under optical control in vivo. Nat Med, 2010; 16(10):1161–1165; doi: 10.1038/nm.2228
MagownP, ShettarB, ZhangY, et al.Direct optical activation of skeletal muscle fibres efficiently controls muscle contraction and attenuates denervation atrophy. Nat Commun, 2015; 6:8506; doi: 10.1038/ncomms9506
12.
SingerML, BenevidesES, RanaS, et al.Optogenetic activation of the tongue in spontaneously breathing mice. Respir Physiol Neurobiol, 2022; 309:103998; doi: 10.1016/j.resp.2022.103998
13.
BruegmannT, MalanD, HesseM, et al.Optogenetic control of heart muscle in vitro and in vivo. Nat Methods, 2010; 7(11):897–900; doi: 10.1038/nmeth.1512
14.
GanjiE, ChanCS, WardCW, et al.Optogenetic activation of muscle contraction in vivo. Connect Tissue Res, 2021; 62(1):15–23; doi: 10.1080/03008207.2020.1798943
15.
BruegmannT, van BremenT, VogtCC, et al.Optogenetic control of contractile function in skeletal muscle. Nat Commun, 2015; 6:7153; doi: 10.1038/ncomms8153
16.
VogtM, SchulzB, WagdiA, et al.Direct optogenetic stimulation of smooth muscle cells to control gastric contractility. Theranostics, 2021; 11(11):5569–5584; doi: 10.7150/thno.53883
17.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12(3):342–347; doi: 10.1038/nm1358
18.
PotterRA, GriffinDA, HellerKN, et al.Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy. Hum Gene Ther, 2021; 32(7–8):375–389; doi: 10.1089/hum.2019.255
19.
CramerML, ShaoG, Rodino-KlapacLR, et al.Induction of T-cell infiltration and programmed death ligand 2 expression by adeno-associated virus in rhesus macaque skeletal muscle and modulation by prednisone. Hum Gene Ther, 2017; 28(6):493–509; doi: 10.1089/hum.2016.113
MendellJR, SahenkZ, LehmanK, et al.Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: A nonrandomized controlled trial. JAMA Neurol, 2020; 77(9):1122–1131; doi: 10.1001/jamaneurol.2020.1484
22.
PhilippidisA. Fourth boy dies in clinical trial of Astellas' AT132. Hum Gene Ther, 2021; 32(19–20):1008–1010; doi: 10.1089/hum.2021.29182.bfs
23.
VogtCC, BruegmannT, MalanD, et al.Systemic gene transfer enables optogenetic pacing of mouse hearts. Cardiovasc Res, 2015; 106(2):338–343; doi: 10.1093/cvr/cvv004
24.
BruegmannT, BoylePM, VogtCC, et al.Optogenetic defibrillation terminates ventricular arrhythmia in mouse hearts and human simulations. J Clin Invest, 2016; 126(10):3894–3904; doi: 10.1172/JCI88950
25.
CortiM, CleaverB, ClementN, et al.Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe Disease: Preclinical to clinical planning. Hum Gene Ther Clin Dev, 2015; 26(3):185–193; doi: 10.1089/humc.2015.068
26.
WesthausA, Cabanes-CreusM, RybickiA, et al.High-throughput in vitro, ex vivo, and in vivo screen of adeno-associated virus vectors based on physical and functional transduction. Hum Gene Ther, 2020; 31(9–10):575–589; doi: 10.1089/hum.2019.264
27.
BowlesDE, McPheeSW, LiC, et al.Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther, 2012; 20(2):443–455; doi: 10.1038/mt.2011.237
28.
TabebordbarM, LagerborgKA, StantonA, et al.Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell, 2021; 184(19):4919–4938 e22; doi: 10.1016/j.cell.2021.08.028
29.
WeinmannJ, WeisS, SippelJ, et al.Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat Commun, 2020; 11(1):5432; doi: 10.1038/s41467-020-19230-w
30.
MarroneL, MarchiPM, AzzouzM. Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders. Expert Opin Biol Ther, 2022; 22(9):1163–1176; doi: 10.1080/14712598.2022.2012148
31.
WuY, LiSS, JinX, et al.Optogenetic approach for functional assays of the cardiovascular system by light activation of the vascular smooth muscle. Vascul Pharmacol, 2015; 71:192–200; doi: 10.1016/j.vph.2015.03.006
32.
WangB, LiJ, FuFH, et al.Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther, 2008; 15(22):1489–1499; doi: 10.1038/gt.2008.104
33.
MendellJR, Rodino-KlapacLR, Rosales-QuinteroX, et al.Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol, 2009; 66(3):290–297; doi: 10.1002/ana.21732
34.
MendellJR, Rodino-KlapacLR, RosalesXQ, et al.Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol, 2010; 68(5):629–638; doi: 10.1002/ana.22251
35.
SalvaMZ, HimedaCL, TaiPW, et al.Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther, 2007; 15(2):320–329; doi: 10.1038/sj.mt.6300027
36.
SunB, YoungSP, LiP, et al.Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. Mol Ther, 2008; 16(8):1366–1371; doi: 10.1038/mt.2008.133
37.
PiekarowiczK, BertrandAT, AzibaniF, et al.A muscle hybrid promoter as a novel tool for gene therapy. Mol Ther Methods Clin Dev, 2019; 15:157–169; doi: 10.1016/j.omtm.2019.09.001
KleinlogelS, FeldbauerK, DempskiRE, et al.Ultra light-sensitive and fast neuronal activation with the Ca2+-permeable channelrhodopsin CatCh. Nat Neurosci, 2011; 14(4):513–518; doi: 10.1038/nn.2776
40.
WagdiA, MalanD, SathyanarayananU, et al.Selective optogenetic control of G(q) signaling using human Neuropsin. Nat Commun, 2022; 13(1):1765; doi: 10.1038/s41467-022-29265-w
41.
ParkJH, HongJK, JangJY, et al.Optogenetic modulation of urinary bladder contraction for lower urinary tract dysfunction. Sci Rep, 2017; 7:40872; doi: 10.1038/srep40872
42.
LehtinenK, NokiaMS, TakalaH. Red light optogenetics in neuroscience. Front Cell Neurosci, 2021; 15:778900; doi: 10.3389/fncel.2021.778900
43.
SahelJA, Boulanger-ScemamaE, PagotC, et al.Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med, 2021; 27(7):1223–1229; doi: 10.1038/s41591-021-01351-4
44.
MaimonBE, SparksK, SrinivasanS, et al.Spectrally distinct channelrhodopsins for two-colour optogenetic peripheral nerve stimulation. Nat Biomed Eng, 2018; 2(7):485–496; doi: 10.1038/s41551-018-0255-5
45.
KlapoetkeNC, MurataY, KimSS, et al.Independent optical excitation of distinct neural populations. Nat Methods, 2014; 11(3):338–346; doi: 10.1038/nmeth.2836
46.
KoptonRA, BaillieJS, RaffertySA, et al.Cardiac electrophysiological effects of light-activated chloride channels. Front Physiol, 2018; 9:1806; doi: 10.3389/fphys.2018.01806
47.
StanleyCE, MaussAS, BorstA, et al.The effects of chloride flux on drosophila heart rate. Methods Protoc, 2019; 2(3):73; doi: 10.3390/mps2030073
48.
GovorunovaEG, CunhaSR, SineshchekovOA, et al.Anion channelrhodopsins for inhibitory cardiac optogenetics. Sci Rep, 2016; 6(1):33530; doi: 10.1038/srep33530
49.
StudemannT, RossingerJ, MantheyC, et al.Contractile force of transplanted cardiomyocytes actively supports heart function after injury. Circulation, 2022; 146(15):1159–1169; doi: 10.1161/CIRCULATIONAHA.122.060124
VierockJ, PeterE, GrimmC, et al.WiChR, a highly potassium-selective channelrhodopsin for low-light one- and two-photon inhibition of excitable cells. Sci Adv, 2022; 8(49):eadd7729; doi: 10.1126/sciadv.add7729
52.
NagelG, SzellasT, HuhnW, et al.Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proc Natl Acad Sci U S A, 2003; 100(24):13940–13945; doi: 10.1073/pnas.1936192100
53.
LinJY. A user's guide to channelrhodopsin variants: Features, limitations and future developments. Exp Physiol, 2011; 96(1):19–25; doi: 10.1113/expphysiol.2009.051961
54.
LinJY, KnutsenPM, MullerA, et al.ReaChR: A red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation. Nat Neurosci, 2013; 16(10):1499–1508; doi: 10.1038/nn.3502
55.
KleinlogelS, FeldbauerK, DempskiRE, et al.Ultra light-sensitive and fast neuronal activation with the Ca(2)+-permeable channelrhodopsin CatCh. Nat Neurosci, 2011; 14(4):513–518; doi: 10.1038/nn.2776
56.
GongX, Mendoza-HallidayD, TingJT, et al.An ultra-sensitive step-function opsin for minimally invasive optogenetic stimulation in mice and macaques. Neuron, 2020; 107(1):38–51 e8; doi: 10.1016/j.neuron.2020.03.032
57.
BamannC, GuetaR, KleinlogelS, et al.Structural guidance of the photocycle of channelrhodopsin-2 by an interhelical hydrogen bond. Biochemistry, 2010; 49(2):267–278; doi: 10.1021/bi901634p
58.
ArnettAL, KoniecznyP, RamosJN, et al.Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. Mol Ther Methods Clin Dev, 2014; 1:14038; doi: 10.1038/mtm.2014.38
59.
NayakS, SarkarD, PerrinGQ, et al.Prevention and reversal of antibody responses against factor IX in gene therapy for hemophilia B. Front Microbiol, 2011; 2:244; doi: 10.3389/fmicb.2011.00244
60.
ChirmuleN, PropertK, MagosinS, et al.Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther, 1999; 6(9):1574–1583; doi: 10.1038/sj.gt.3300994
61.
KurandaK, Jean-AlphonseP, LeborgneC, et al.Exposure to wild-type AAV drives distinct capsid immunity profiles in humans. J Clin Invest, 2018; 128(12):5267–5279; doi: 10.1172/JCI122372
62.
GernouxG, GruntmanAM, BlackwoodM, et al.Muscle-directed delivery of an AAV1 vector leads to capsid-specific T cell exhaustion in nonhuman primates and humans. Mol Ther, 2020; 28(3):747–757; doi: 10.1016/j.ymthe.2020.01.004
63.
Samelson-JonesBJ, FinnJD, FavaroP, et al.Timing of intensive immunosuppression impacts risk of transgene antibodies after AAV gene therapy in nonhuman primates. Mol Ther Methods Clin Dev, 2020; 17:1129–1138; doi: 10.1016/j.omtm.2020.05.001
64.
MingozziF, HasbrouckNC, Basner-TschakarjanE, et al.Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 2007; 110(7):2334–2341; doi: 10.1182/blood-2007-03-080093
65.
MelianiA, BoisgeraultF, HardetR, et al.Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun, 2018; 9(1):4098; doi: 10.1038/s41467-018-06621-3
66.
MickleAD, WonSM, NohKN, et al.A wireless closed-loop system for optogenetic peripheral neuromodulation. Nature, 2019; 565(7739):361–365; doi: 10.1038/s41586-018-0823-6
67.
WangY, XieK, YueH, et al.Flexible and fully implantable upconversion device for wireless optogenetic stimulation of the spinal cord in behaving animals. Nanoscale, 2020; 12(4):2406–2414; doi: 10.1039/c9nr07583f
68.
WuX, ZhuX, ChongP, et al.Sono-optogenetics facilitated by a circulation-delivered rechargeable light source for minimally invasive optogenetics. Proc Natl Acad Sci U S A, 2019; 116(52):26332–26342; doi: 10.1073/pnas.1914387116
69.
GauvainG, AkolkarH, ChaffiolA, et al.Optogenetic therapy: High spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates. Commun Biol, 2021; 4(1):125; doi: 10.1038/s42003-020-01594-w
70.
NussinovitchU, GepsteinL. Optogenetics for in vivo cardiac pacing and resynchronization therapies. Nat Biotechnol, 2015; 33(7):750–754; doi: 10.1038/nbt.3268
71.
CrociniC, FerrantiniC, CoppiniR, et al.Optogenetics design of mechanistically-based stimulation patterns for cardiac defibrillation. Sci Rep, 2016; 6(1):35628; doi: 10.1038/srep35628
72.
BruegmannT, BeiertT, VogtCC, et al.Optogenetic termination of atrial fibrillation in mice. Cardiovasc Res, 2018; 114(5):713–723; doi: 10.1093/cvr/cvx250
73.
NynsECA, KipA, BartCI, et al.Optogenetic termination of ventricular arrhythmias in the whole heart: Towards biological cardiac rhythm management. Eur Heart J, 2017; 38(27):2132–2136; doi: 10.1093/eurheartj/ehw574
74.
Quiñonez UribeRA, LutherS, Diaz-MaueL, et al.Energy-reduced arrhythmia termination using global photostimulation in optogenetic murine hearts. Front Physiol, 2018; 9:1651; doi: 10.3389/fphys.2018.01651
75.
AusraJ, MadridM, YinRT, et al.Wireless, fully implantable cardiac stimulation and recording with on-device computation for closed-loop pacing and defibrillation. Sci Adv, 2022; 8(43):eabq7469; doi: 10.1126/sciadv.abq7469
76.
NynsECA, PoelmaRH, VolkersL, et al.An automated hybrid bioelectronic system for autogenous restoration of sinus rhythm in atrial fibrillation. Sci Transl Med, 2019; 11(481):aau6447; doi: 10.1126/scitranslmed.aau6447
77.
SasseP, FunkenM, BeiertT, et al.Optogenetic termination of cardiac arrhythmia: Mechanistic enlightenment and therapeutic application?. Front Physiol, 2019; 10:675; doi: 10.3389/fphys.2019.00675
78.
BenevidesES, SunshineMD, RanaS, et al.Optogenetic activation of the diaphragm. Sci Rep, 2022; 12(1):6503; doi: 10.1038/s41598-022-10240-w
79.
SpaldingKL, BhardwajRD, BuchholzBA, et al.Retrospective birth dating of cells in humans. Cell, 2005; 122(1):133–143; doi: 10.1016/j.cell.2005.04.028
